Theresa M. Im
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Theresa M. Im has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Darios Getahun
Department of Research & Evaluation Kaiser Permanente Southern California Pasadena CA USA
11 shared publications - Fagen Xie
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States
9 shared publications - Michael J. Fassett
Department of Obstetrics and Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, CA, United States
9 shared publications - Vicki Y. Chiu
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States
9 shared publications - Jiaxiao Shi
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States
8 shared publications - Harpreet S. Takhar
Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California
5 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Pediatrics and Parenting
- Vol.Ā 9, e88772
Health Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study
Background: Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although antiāRhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. Objective: This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. Methods: We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processingāassisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ā„2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. Results: Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ā„35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. Conclusions: HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.
- 5 June 2026
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Pediatrics and Parenting
- Vol.Ā 9, e88772
Open AccessHealth Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study
Background: Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although antiāRhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. Objective: This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. Methods: We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processingāassisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ā„2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. Results: Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ā„35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. Conclusions: HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.
- Open Access
- 9 December 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Research Protocols
- Vol.Ā 14, e77836
Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies
Background: Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. Objective: This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. Methods: We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processingāassisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. Results: The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. Conclusions: We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processingāassisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. International Registered Report Identifier (IRRID): DERR1-10.2196/77836
- 9 December 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Research Protocols
- Vol.Ā 14, e77836
Open AccessFeasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies
Background: Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. Objective: This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. Methods: We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processingāassisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. Results: The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. Conclusions: We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processingāassisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. International Registered Report Identifier (IRRID): DERR1-10.2196/77836
- Open Access
- 2 December 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Preprints
Health Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study (Preprint)
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although antiāRhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. OBJECTIVE This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. METHODS We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processingāassisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ā„2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. RESULTS Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ā„35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. CONCLUSIONS HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.
- 2 December 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Preprints
Open AccessHealth Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study (Preprint)
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility. Although antiāRhesus D (RhD) prophylaxis has reduced RhD-associated cases, HDFN persists due to non-RhD antibodies and gaps in prevention. Population-based data on maternal and neonatal outcomes and recurrence patterns are limited. OBJECTIVE This study aimed to characterize maternal and neonatal outcomes, health care use patterns, and recurrence rates of HDFN across pregnancies. METHODS We conducted a retrospective cohort study of 464,711 pregnancies within the Kaiser Permanente Southern California system from January 1, 2008, to June 30, 2022. HDFN diagnoses were confirmed using validated natural language processingāassisted manual chart review and followed through 2023. Maternal characteristics, neonatal outcomes, and health care use were compared by HDFN status, and recurrence patterns were evaluated among individuals with ā„2 pregnancies. Chi-square tests and Wilcoxon rank-sum tests were used to compare characteristics between HDFN and non-HDFN pregnancies. Statistical significance was defined as P<.05. RESULTS Among all pregnancies, 139 of 464,711 (0.03%) were diagnosed with HDFN. Women with HDFN were more likely than those without HDFN to be older (aged ā„35 years; n=42, 30.2% vs n=97,146, 20.9%) and multiparous (n=121, 87.1% vs n=264,766, 57%). Infants affected by HDFN had higher rates of preterm birth (n=40, 28.4% vs n=42,240, 9.5%), low birth weight (<2500 g; n=22, 15.6% vs n=31,740, 7.1%), and neonatal jaundice (n=92, 65.2% vs n=162,465, 36.4%) than non-HDFN infants. Delivery hospitalizations (median 5.0, IQR 2.0-7.5 days vs median 2.0, IQR 1.0-2.0 days) and neonatal intensive care unit stays (median 4.0, IQR 0.0-7.0 days vs median 0.0, IQR 0.0-0.0 days) were longer, and maternal nondelivery hospitalizations were more frequent (n=27, 19.4% vs n=23,228, 5%) among pregnancies complicated by HDFN. Among women with a prior HDFN-affected pregnancy, 83.3% (n=25) experienced recurrence in a subsequent pregnancy. Of these recurrent cases, 32% (n=8) were severe, and 75% (n=6) involved fetal anemia requiring at least 1 intrauterine transfusion. CONCLUSIONS HDFN was rare but was associated with substantial maternal and neonatal morbidity, including higher rates of preterm birth, increased neonatal intensive care unit admissions, and greater health care use. Recurrence was frequent and clinically significant, underscoring the importance of early surveillance and proactive management strategies.
- Open Access
- 21 May 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Preprints
Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies (Preprint)
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. OBJECTIVE This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. METHODS We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processingāassisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. RESULTS The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. CONCLUSIONS We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processingāassisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77836
- 21 May 2025
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Preprints
Open AccessFeasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies (Preprint)
BACKGROUND Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed. OBJECTIVE This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system. METHODS We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processingāassisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status. RESULTS The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse. CONCLUSIONS We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processingāassisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77836
- 5 April 2022
- Published byĀ ElsevierĀ inĀ American Journal of Obstetrics and Gynecology
- Vol.Ā 227 Ā (1) , 57.e1-57.e13
Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study
- 5 April 2022
- Published byĀ ElsevierĀ inĀ American Journal of Obstetrics and Gynecology
- Vol.Ā 227 Ā (1) , 57.e1-57.e13
Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study
- 12 March 2022
- Published byĀ ElsevierĀ inĀ American Journal of Obstetrics and Gynecology
- Vol.Ā 227 Ā (1) , 59.e1-59.e9
Association between menorrhagia and risk of intrauterine deviceārelated uterine perforation and device expulsion: results from the Association of Uterine Perforation and Expulsion of Intrauterine Device study
- 12 March 2022
- Published byĀ ElsevierĀ inĀ American Journal of Obstetrics and Gynecology
- Vol.Ā 227 Ā (1) , 59.e1-59.e9
Association between menorrhagia and risk of intrauterine deviceārelated uterine perforation and device expulsion: results from the Association of Uterine Perforation and Expulsion of Intrauterine Device study
- 1 January 2022
- Published byĀ ElsevierĀ inĀ Contraception
- Vol.Ā 105, 19-25
Ectopic pregnancy prevention: Further evidence of benefits of prescription contraceptives
- 1 January 2022
- Published byĀ ElsevierĀ inĀ Contraception
- Vol.Ā 105, 19-25
Ectopic pregnancy prevention: Further evidence of benefits of prescription contraceptives
- Open Access
- 30 November 2020
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Medical Informatics
- Vol.Ā 8 Ā (11) , e18559
Identifying Ectopic Pregnancy in a Large Integrated Health Care Delivery System: Algorithm Validation
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Surveillance of ectopic pregnancy (EP) using electronic databases is important. There is no study that assessed the validity of EP case ascertainment using electronic health records. Objective: We aimed to assess the validity of an enhanced version of a previously validated algorithm, which used a combination of encounters with EP related diagnostic/procedure codes and methotrexate injections. The enhanced algorithm included ICD-10 diagnostic/procedure codes, used telephone appointment visits, and excluded cases with only abdominal EP diagnosis codes. Methods: Medical records of 500 women, aged 15-44 years with membership at Kaiser Permanente Southern and Northern California between 2009-2018 with a potential EP were randomly selected for chart review and true cases were identified. The sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and the overall performance (Youdenās index and F-score) of the algorithm were evaluated and compared to the validated algorithm. Results: There were 334 true positive and 166 false positive EP cases with available records. True positive and true negative EP cases did not differ significantly according to maternal age, race/ethnicity and smoking status. EP cases with only one encounter and non-tubal EP were more likely to be misclassified. The sensitivity, specificity, PPV, and NPV of the enhanced algorithm for EP were 97.6%, 84.9%, 92.9%, and 94.6%, respectively. The Youden index and F-score were 82.5% and 95.2%. The sensitivity and NPV were lower at 94.3% and 88.1%, respectively, for the previously published algorithm. The sensitivity of surgical procedure codes from electronic chart abstraction to correctly identify surgical management was 91.9%. The overall accuracy, defined as the percentage of EP cases with correct management (surgical, medical, and unclassified) identified by electronic chart abstraction, was 92.3%. Conclusions: The performance of the enhanced algorithm for EP case ascertainment in the integrated healthcare databases is adequate to allow for use in future epidemiological studies. Use of this algorithm will likely result in better capture of true EP cases than the previously validated algorithm.
- 30 November 2020
- Published byĀ JMIR Publications Inc.Ā inĀ JMIR Medical Informatics
- Vol.Ā 8 Ā (11) , e18559
Open AccessIdentifying Ectopic Pregnancy in a Large Integrated Health Care Delivery System: Algorithm Validation
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Surveillance of ectopic pregnancy (EP) using electronic databases is important. There is no study that assessed the validity of EP case ascertainment using electronic health records. Objective: We aimed to assess the validity of an enhanced version of a previously validated algorithm, which used a combination of encounters with EP related diagnostic/procedure codes and methotrexate injections. The enhanced algorithm included ICD-10 diagnostic/procedure codes, used telephone appointment visits, and excluded cases with only abdominal EP diagnosis codes. Methods: Medical records of 500 women, aged 15-44 years with membership at Kaiser Permanente Southern and Northern California between 2009-2018 with a potential EP were randomly selected for chart review and true cases were identified. The sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and the overall performance (Youdenās index and F-score) of the algorithm were evaluated and compared to the validated algorithm. Results: There were 334 true positive and 166 false positive EP cases with available records. True positive and true negative EP cases did not differ significantly according to maternal age, race/ethnicity and smoking status. EP cases with only one encounter and non-tubal EP were more likely to be misclassified. The sensitivity, specificity, PPV, and NPV of the enhanced algorithm for EP were 97.6%, 84.9%, 92.9%, and 94.6%, respectively. The Youden index and F-score were 82.5% and 95.2%. The sensitivity and NPV were lower at 94.3% and 88.1%, respectively, for the previously published algorithm. The sensitivity of surgical procedure codes from electronic chart abstraction to correctly identify surgical management was 91.9%. The overall accuracy, defined as the percentage of EP cases with correct management (surgical, medical, and unclassified) identified by electronic chart abstraction, was 92.3%. Conclusions: The performance of the enhanced algorithm for EP case ascertainment in the integrated healthcare databases is adequate to allow for use in future epidemiological studies. Use of this algorithm will likely result in better capture of true EP cases than the previously validated algorithm.
- 17 November 2020
- Published byĀ Taylor & FrancisĀ inĀ Informatics for Health and Social Care
- Vol.Ā 46 Ā (1) , 18-28
An automated algorithm using free-text clinical notes to improve identification of transgender people
Accurate identification of transgender persons is a critical first step in conducting transgender health studies. To develop an automated algorithm for identifying transgender individuals from electronic medical records (EMR) using free-text clinical notes. The development and validation of the algorithm was based on data from an integrated healthcare system that served as a participating site in the multicenter Study of Transition Outcomes and Gender. The training and test datasets each contained a total of 300 individuals identified between 2006 and 2014. Both datasets underwent a full medical record review by experienced research abstractors. The validated algorithm was then implemented to identify transgender individuals in the EMR using all clinical notes of patients that received care between January 1, 2015 and June 30, 2018. Validation of the algorithm against the full chart review demonstrated a high degree of accuracy with 97% sensitivity, 95% specificity, 94% positive predictive value, and 97% negative predictive value. The algorithm classified 7,409 individuals (3.5%) as āDefinitely transgenderā and 679 individuals (0.3%) as āProbably transgenderā out of 212,138 candidates with a total of 378,641 clinical notes. The computerized NLP algorithm can support essential efforts to improve the health of transgender people.
- 17 November 2020
- Published byĀ Taylor & FrancisĀ inĀ Informatics for Health and Social Care
- Vol.Ā 46 Ā (1) , 18-28
An automated algorithm using free-text clinical notes to improve identification of transgender people
Accurate identification of transgender persons is a critical first step in conducting transgender health studies. To develop an automated algorithm for identifying transgender individuals from electronic medical records (EMR) using free-text clinical notes. The development and validation of the algorithm was based on data from an integrated healthcare system that served as a participating site in the multicenter Study of Transition Outcomes and Gender. The training and test datasets each contained a total of 300 individuals identified between 2006 and 2014. Both datasets underwent a full medical record review by experienced research abstractors. The validated algorithm was then implemented to identify transgender individuals in the EMR using all clinical notes of patients that received care between January 1, 2015 and June 30, 2018. Validation of the algorithm against the full chart review demonstrated a high degree of accuracy with 97% sensitivity, 95% specificity, 94% positive predictive value, and 97% negative predictive value. The algorithm classified 7,409 individuals (3.5%) as āDefinitely transgenderā and 679 individuals (0.3%) as āProbably transgenderā out of 212,138 candidates with a total of 378,641 clinical notes. The computerized NLP algorithm can support essential efforts to improve the health of transgender people.
- Open Access
- 15 July 2020
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical Infectious Diseases
- Vol.Ā 73 Ā (11) , e4454-e4462
Do Inpatient Antimicrobial Stewardship Programs Help Us in the Battle Against Antimicrobial Resistance?
Antibiotic stewardship programs (ASPs) have demonstrated success at reducing costs, yet there is limited quality evidence of their effectiveness to reduce infections of high-profile drug-resistant organisms. This retrospective cohort study included all Kaiser Permanente Southern California (KPSC) members hospitalized in 9 KPSC hospitals aged ā„18 years from January 1, 2008 to December 31, 2016. We measured the impact of staggered ASP implementation on consumption of 18 ASP-targeted antibiotics using generalized linear mixed effects models. We used multivariable generalized linear mixed effects models to estimate the adjusted effect of ASP on rates of infection with drug-resistant organisms. Analyses were adjusted for confounding by time, cluster effects, and patient-level and hospital-level characteristics. We included 765,111 hospitalizations (288,257 pre-ASP, 476,854 post-ASP). By defined daily dose, we found a 6.1% (-7.5% - -4.7%) overall decrease in use of antibiotics post-ASP, and by days of therapy, we detected a 4.3% (-5.4% - -3.1%) decrease in overall use of antibiotics. The number of prescriptions increased post-ASP (1.04 [1.03ā1.05]). In adjusted analyses, we detected an overall increase of VRE infection following ASP (1.37 [1.10-1.69]). We did not detect a change in the rates of ESBL, CRE and MDR Pseudomonas aeruginosa following ASP. ASPs with successful reductions in consumption of targeted antibiotics may not see changes in infection rates with antibiotic-resistant organisms in the 2 to 6 years post-implementation. There are likely differing timescales for reversion to susceptibility across organisms and antibiotics, and unintended consequences from compensatory prescribing may occur.
- 15 July 2020
- Published byĀ Oxford University Press (OUP)Ā inĀ Clinical Infectious Diseases
- Vol.Ā 73 Ā (11) , e4454-e4462
Open AccessDo Inpatient Antimicrobial Stewardship Programs Help Us in the Battle Against Antimicrobial Resistance?
Antibiotic stewardship programs (ASPs) have demonstrated success at reducing costs, yet there is limited quality evidence of their effectiveness to reduce infections of high-profile drug-resistant organisms. This retrospective cohort study included all Kaiser Permanente Southern California (KPSC) members hospitalized in 9 KPSC hospitals aged ā„18 years from January 1, 2008 to December 31, 2016. We measured the impact of staggered ASP implementation on consumption of 18 ASP-targeted antibiotics using generalized linear mixed effects models. We used multivariable generalized linear mixed effects models to estimate the adjusted effect of ASP on rates of infection with drug-resistant organisms. Analyses were adjusted for confounding by time, cluster effects, and patient-level and hospital-level characteristics. We included 765,111 hospitalizations (288,257 pre-ASP, 476,854 post-ASP). By defined daily dose, we found a 6.1% (-7.5% - -4.7%) overall decrease in use of antibiotics post-ASP, and by days of therapy, we detected a 4.3% (-5.4% - -3.1%) decrease in overall use of antibiotics. The number of prescriptions increased post-ASP (1.04 [1.03ā1.05]). In adjusted analyses, we detected an overall increase of VRE infection following ASP (1.37 [1.10-1.69]). We did not detect a change in the rates of ESBL, CRE and MDR Pseudomonas aeruginosa following ASP. ASPs with successful reductions in consumption of targeted antibiotics may not see changes in infection rates with antibiotic-resistant organisms in the 2 to 6 years post-implementation. There are likely differing timescales for reversion to susceptibility across organisms and antibiotics, and unintended consequences from compensatory prescribing may occur.